CTLA4 and neoplasm: Unconjugated LIGHT, did not confer a survival advantage relative to the survival of untreated miceLIGHT-VTP treatment led to weight loss (ns) and 4-week survival advantage. Following 7 weeks of treatment, tumours in RIP1-Tag5 mice treated with LIGHT-VTP were similar in appearance to those in untreated mice. More cell death in treatment groupLIGHT-VTP plus checkpoint blockade of both CTLA-4 and PD-1 increased the mean survival of mice from 30 weeks (with LIGHT-VTP monotherapy) to 36 weeks